Huang Ruili, Wallqvist Anders, Covell David G
National Cancer Institute at Frederick, Developmental Therapeutics Program, Screening Technologies Branch, Laboratory of Computational Technologies, Frederick, MD 21702, USA.
Biochem Pharmacol. 2005 Apr 1;69(7):1009-39. doi: 10.1016/j.bcp.2005.01.001.
Clustering analysis of tumor cell cytotoxicity profiles for the National Cancer Institute (NCI)'s open compound repository has been used to catalog over 1100 metal or metalloid containing compounds with potential anticancer activity. The molecular features and corresponding reactivity of these compounds have been analyzed in terms of properties of their metals, their associated organic components (ligands) and their capacity to inhibit tumor cell growth. Cytotoxic responses are influenced by both the identity of the metal and the properties of its coordination ligand, with clear associations between structural similarities and cytotoxicity. Assignments of mechanisms of action (MOAs) for these compounds could be segregated into four broad response classes according to preference for binding to biological sulfhydryl groups, chelation, generation of reactive oxygen species (ROS), and production of lipophilic ions. Correlations between specific cytotoxic responses and differential gene expression profiles within the NCI's tumor cell panel serve as a validation for candidate biological targets and putative MOA classes. In addition, specific sensitivity toward subsets of metal containing agents has been found for certain tumor cell panels. Taken together, our results expand the knowledge base available for evaluating, designing and developing new metal-based anticancer drugs that may provide the basis for target-specific therapeutics.
针对美国国立癌症研究所(NCI)的开放化合物储存库,对肿瘤细胞细胞毒性谱进行聚类分析,已用于对1100多种具有潜在抗癌活性的含金属或类金属化合物进行编目。这些化合物的分子特征和相应的反应活性已根据其金属特性、相关有机成分(配体)及其抑制肿瘤细胞生长的能力进行了分析。细胞毒性反应受金属的特性及其配位配体的性质影响,结构相似性与细胞毒性之间存在明显关联。根据这些化合物与生物巯基结合的偏好、螯合作用、活性氧(ROS)的产生以及亲脂性离子的产生,这些化合物的作用机制(MOA)可分为四大反应类别。NCI肿瘤细胞组内特定细胞毒性反应与差异基因表达谱之间的相关性,可作为候选生物靶点和假定MOA类别的验证。此外,已发现某些肿瘤细胞组对含金属药物亚组具有特定敏感性。综上所述,我们的研究结果扩展了可用于评估、设计和开发新型金属基抗癌药物的知识库,这些药物可能为靶向特异性治疗提供基础。